Compounders Research Compare

Climb Bio, Inc.(CLYM)

Biotechnology · Wellesley Hills, MA

$10.93-0.12 (-1.09%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

About Climb Bio, Inc.

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Wellesley Hills, MA

28 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Aoife Brennan BCh MMSc

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T14:46:10.508Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:46:10.508Z.

Quote observation: 2026-10-06T14:45:06.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 625,884,590
Total debt · period ending 2026-06-30: 1,314,000
Cash · period ending 2026-06-30: 44,107,000
TTM operating income · period ending 2026-06-30: -64,758,000

FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CLYM EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CLYM Competitors' EV/EBIT Ratio

Climb Bio, Inc.

Current

Market Cap

$625.88M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aura Biosciences, Inc.

Market Cap

$633.09M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AngioDynamics, Inc.

Market Cap

$611.72M

EV/EBIT Ratio

N/A

TTM Avg

596.45x

3Y Avg

263.81x

5Y Avg

279.32x

OmniAb, Inc.

Market Cap

$643.59M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fulgent Genetics, Inc.

Market Cap

$602.80M

EV/EBIT Ratio

N/A

TTM Avg

2.85x

3Y Avg

52.42x

5Y Avg

52.42x

4D Molecular Therapeutics, Inc.

Market Cap

$651.36M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Ironwood Pharmaceuticals, Inc.

Market Cap

$591.78M

EV/EBIT Ratio

3.85x

TTM Avg

7.80x

3Y Avg

8.99x

5Y Avg

8.51x

Helus Pharma Inc.

Market Cap

$661.57M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MiMedx Group, Inc.

Market Cap

$664.59M

EV/EBIT Ratio

60.59x

TTM Avg

21.67x

3Y Avg

25.85x

5Y Avg

35.25x

OrthoPediatrics Corp.

Market Cap

$581.51M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Climb Bio, Inc. (CLYM)	$625.88M	N/A	N/A	N/A	N/A
Aura Biosciences, Inc. (AURA)vs ›	$633.09M	N/A	N/A	N/A	N/A
AngioDynamics, Inc. (ANGO)vs ›	$611.72M	N/A	596.45x	263.81x	279.32x
OmniAb, Inc. (OABI)vs ›	$643.59M	N/A	N/A	N/A	N/A
Fulgent Genetics, Inc. (FLGT)vs ›	$602.80M	N/A	2.85x	52.42x	52.42x
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$651.36M	N/A	N/A	N/A	N/A
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$591.78M	3.85x	7.80x	8.99x	8.51x
Helus Pharma Inc. (HELP)vs ›	$661.57M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$664.59M	60.59x	21.67x	25.85x	35.25x
OrthoPediatrics Corp. (KIDS)vs ›	$581.51M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics